View in EDS PDF Full Text

Lack of Benefit of Intravenous Synthetic Human Secretin in the Treatment of Autism.

Saved in:
Bibliographic Details
Title: Lack of Benefit of Intravenous Synthetic Human Secretin in the Treatment of Autism.
Authors: Molloy CA (AUTHOR), Manning-Courtney P (AUTHOR), Swayne S (AUTHOR), Bean J (AUTHOR), Brown JM (AUTHOR), Murray DS (AUTHOR), Kinsman AM (AUTHOR), Brasington M (AUTHOR), Ulrich CD II (AUTHOR)
Source: Journal of Autism & Developmental Disorders. Dec2002, Vol. 32 Issue 6, p545-545. 1p.
Abstract: The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism. Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial. One group received 2 IU/kg of intravenous synthetic human secretin at the first visit, followed by an equal volume of intravenous saline placebo at week 6. The other group received treatments in the reverse order. All children were evaluated at weeks 1, 3, 6, 9, and 12 with standardized assessments of language, behavior, and autism symptomatology. There were no significant differences in the mean scores on any measure of language, behavior, or autism symptom severity after treatment with secretin compared to treatment with placebo. The results of this study do not support secretin as a treatment for autism. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Autism & Developmental Disorders is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism. Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial. One group received 2 IU/kg of intravenous synthetic human secretin at the first visit, followed by an equal volume of intravenous saline placebo at week 6. The other group received treatments in the reverse order. All children were evaluated at weeks 1, 3, 6, 9, and 12 with standardized assessments of language, behavior, and autism symptomatology. There were no significant differences in the mean scores on any measure of language, behavior, or autism symptom severity after treatment with secretin compared to treatment with placebo. The results of this study do not support secretin as a treatment for autism. [ABSTRACT FROM AUTHOR]
ISSN:01623257
DOI:10.1023/a:1021202930206